Table 1.

Patient and treatment characteristics by severity of hematologic toxicity

Characteristic	No HT3+		HT3+		P-valuea
	n	(%)	n	(%)
Total	39	100.0	21	100.0
Sex					.606
Female	2	5.1	2	9.5
Male	37	94.9	19	90.5
Histology					.039
Adenocarcinoma	39	100.0	18	85.7
Squamous cell carcinoma	0	0.0	2	9.5
Adenosquamous	0	0.0	1	4.8
Stage					.326
IB	2	5.1	0	0.0
IIA	6	15.4	2	9.5
IIB	7	17.9	4	19.0
IIIA	20	51.3	9	42.9
IIIB	2	5.1	2	9.5
IIIC	1	2.6	0	0.0
IV	0	0.0	3	14.3
N/A	1	2.6	1	4.8
Treatment intent					.143
Neoadjuvant	35	89.7	15	71.4
Definitive	4	10.3	6	28.6
Radiation therapy modality					.119
IMRT	39	100.0	19	90.5
3-dimensional CRT	0	0.0	2	9.5
Concurrent chemotherapy					.154
Carboplatin and paclitaxel	29	74.4	12	57.1
5-FU/capecitabine with platinum agent	8	20.5	9	42.9
5-FU/capecitabine alone	2	5.1	0	0.0

5-FU, 5-flurouracil; CRT, conformal radiation therapy; HT3+, grade ≥3 hematologic toxicity; IMRT, intensity modulated radiation therapy.

^aFisher's exact test P-value.